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Abstract
We evaluated factors associated with normalization of the absolute CD4+ T-cell counts, per cent CD4+ T cells and CD4+/CD8+ T-cell
ratio. A multicentre observational study was carried out in patients with sustained HIV-RNA <50 copies/mL. Outcomes were: CD4-
count >500/mm3 and multiple T-cell marker recovery (MTMR), deﬁned as CD4+ T cells >500/mm3 plus %CD4 T cells >29% plus
CD4+/CD8+ T-cell ratio >1. Kaplan–Meier survival analysis and Cox regression analyses to predict odds for achieving outcomes were
performed. Three hundred and ﬁfty-two patients were included and followed-up for a median of 4.1 (IQR 2.1–5.9) years, 270 (76.7%)
achieving a CD4+ T-cell count >500 cells/mm3 and 197 (56%) achieving MTMR. Using three separate Cox models for both outcomes
we demonstrated that independent predictors were: both absolute CD4+ and CD8+ T-cell counts, %CD4+ T cells, a higher CD4+/
CD8+ T-cell ratio, and age. A likelihood-ratio test showed signiﬁcant improvements in ﬁtness for the prediction of either CD4+ >500/
mm3 or MTMR by multivariable analysis when the other immune markers at baseline, besides the absolute CD4+ count alone, were
considered. In addition to baseline absolute CD4+ T-cell counts, pretreatment %CD4+ T cells and the CD4+/CD8+ T-cell ratio inﬂu-
ence recovery of T-cell markers, and their consideration should inﬂuence the decision to start antiretroviral therapy. However, owing
to the small sample size, further studies are needed to conﬁrm these results in relation to clinical endpoints.
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Introduction
Following HIV infection, CD4+ and CD8+ T-lymphocyte
homeostasis is regulated on the basis of absolute T-lympho-
cyte counts (CD8+ counts increase as CD4+ counts decline)
until advanced stages of disease when the CD8+ count also
declines. [1]. Many patients receiving effective antiretroviral
therapy (ARV) (those who maintain undetectable plasma HIV
RNA levels) experience signiﬁcant increases in absolute
CD4-counts [2,3]. The attainment of a CD4+ T-cell count
greater than 500 cells/mm3 has been associated with a
reduction in mortality rates to the level of the general popu-
lation [4]. Although a signiﬁcant proportion of patients start-
ing therapy with CD4+ T-cell counts <350 cells/mm3
achieves this goal [5–7], about 25–30% of patients do not
[8]. Host factors, including pretreatment CD4+ T cells, are
important predictors of immunological recovery [5–7,9–11].
More recently, attention has focused on levels of immune
activation as a correlate of blunted CD4+ T-cell recovery
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[12] and an independent predictor of mortality [13], often
from non-AIDS related conditions [14].
Most studies focused on CD4+ T-cell count increases as
the principal sign of immunological recovery after initiation
of antiretroviral therapy, but other T-cell markers may have
important prognostic value. Castagna et al.[15] found that
the percentage of CD4+ T cells (%CD4+) predicts the abso-
lute magnitude of CD4+ T-cell count recovery over a short
period of follow-up, and both %CD4+ T cells and the
CD4+/CD8+ T-cell ratio predict risk for AIDS-related [16]
and non-AIDS related morbidities [17–19]. To what extent
the %CD4+ T cells and CD4+/CD8+ T-cell ratio normalize
after prolonged periods of effective antiretroviral therapy has
yet to be described.
Therefore, we undertook an analysis of a large cohort of
patients experiencing suppressive antiretroviral therapy
to characterize the recovery of multiple T-lymphocyte
parameters after prolonged periods of suppression of virus
replication. We describe the proportions of patients who
achieve increases in absolute CD4+ T-cell counts to a value
>500 cells/mm3, as well as a multiparametric measure of
T-cell recovery (multiple T-cell marker recovery, MTMR),
deﬁned as absolute CD4+ T-cell counts, %CD4+ T cells
and CD4+/CD8+ T-cell ratio above normal levels.
Methods
Design of the study and cohort
We conducted a retrospective analysis of patients enrolled
in the Italian MASTER (Management of Standardized Evalua-
tion of Retroviral HIV Infection) study, a longitudinal multi-
centre cohort in nine referral centres throughout Italy
(http://www.mastercohort.it). The distinguishing characteris-
tic of this cohort is that data are compiled in a common
electronic chart (Health & Notes 3.5, Healthware S.p.A.,
Naples, Italy) in use in the participating centres. Data are
recorded over a standardized time-scale every 3 months,
with merging and data cleaning performed at a single centre
every 6 months.
Inclusion criteria and data collection
Patients included in this study commenced antiretroviral
therapy between 2000 and 2005, with regimens consisting of
two nucleoside/tide reverse transcriptase inhibitors (NRTI)
plus: (i) a protease inhibitor (PI) ± low-dose ritonavir (PI/r)
as a booster, (ii) a non-nucleoside reverse transcriptase
inhibitor (NNRTI) or (iii) abacavir. Patients had to achieve an
HIV-1 RNA level <50 copies/mL within the ﬁrst 12 months
and maintain a viral load below this threshold for ‡2 years.
Patients had to have at least two HIV-1 RNA determinations
per year. Absolute CD4+ and CD8+ T-cell counts, %CD4+
and %CD8+ T cells and CD4+/CD8+ T-cell ratios were col-
lected at pretreatment [baseline, i.e. within 6 months before
highly active antiretroviral therapy (HAART) initiation] and
follow-up time-points. Subjects gave written informed con-
sent for participation in the observational cohort, and each
site obtained approval by their Ethics Committee.
Study outcomes and additional deﬁnitions of immune status
We selected two different primary immunological outcomes:
the achievement of a CD4+ T-cell count >500 cells/mm3 and
the achievement of MTMR, comprising a CD4+ T-cell count
>500 cells/mm3 plus a %CD4+ T cells >29% plus a CD4+/
CD8+ T-cell ratio >1. A patient’s follow-up was censored at
death, at loss to follow-up, or at an increase in HIV-1 RNA
>50 copies/mL, whichever occurred ﬁrst.
To evaluate whether immune markers below a certain
degree of immune impairment could predict the outcomes
and to evaluate discordance in deﬁning a certain stage of
immune suppression, the following cut-offs were deﬁned:
[1,14]: (i) CD4+ T-cell count £200 cells/mm3 and %CD4+
T cells £14% and CD4+/CD8+ T-cell ratio £0.3; (ii) CD4+
T-cell count £350 cells/mm3 and %CD4+ T cells £20% and
CD4+/CD8+ T-cell ratio £0.5; and (iii) CD4+ T-cell count
£500 cells/mm3 and %CD4+ T cells £29% and CD4+/CD8+
T-cell ratio£1.
Statistical analysis
Predictors of immune recovery. Time to endpoints was assessed
by Kaplan–Meier survival curves. Date of ARV initiation was
chosen as the starting point. Univariate and multivariable
Cox regression models were used to assess relative hazards
of CD4+ T-cell recovery >500/mm3 and MTMR, considering
both baseline and time-updated covariates, with a robust var-
iance computation by a grouped jackknife [20,21].
The models included baseline T-cell parameters (ﬁtted as
numeric) combined in separate multivariable models as fol-
lows: (i) absolute CD4+ and absolute CD8+ T-cell counts
(model 1); (ii) %CD4 and %CD8 T cells (model 2); and (iii)
CD4+/CD8+ T-cell ratio (model 3). Also, categorical abso-
lute CD4+ T-cell counts (> or £350/mm3) and CD4+/CD8+
T-cell ratio (> or £0.5) were tested as independent variables
because 350 CD4+/mm3, corresponding to a CD4+/CD8+
T-cell ratio of 0.5, has been indicated as a landmark thresh-
old for starting therapy [22].
Moreover, the models included the time-ﬁxed covariates
at baseline of age, gender, mode of HIV transmission, calen-
dar year, HCV/HBV co-infection status and HIV RNA level.
Time-varying covariates included type of anchor drug (PI/r,
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PI, NNRTI, abacavir), regimen number (deﬁned as any single
drug modiﬁcation occurring during the follow-up), and num-
ber of AIDS-deﬁning events or non-AIDS-related illnesses
and neoplasias.
Comparison between absolute CD4+ T-cell count and composite
measures of immune status at baseline for predictions of immune
recovery. Absolute CD4+ T-cell counts and composite
measures of T-cell status at baseline were compared for
predictions of immune recovery in order to verify if the
inclusion of one or more additional covariates would lead to
a signiﬁcant improvement in a model ﬁt. For this analysis,
likelihood ratio tests (LRTs) were executed [23]. Two base/
null models were set up, one ﬁtted with the sole baseline
CD4+ T-cell count and another with the sole baseline
CD4+/CD8+ T-cell ratio. More complex/alternative models
considered were those ﬁtted with the base variable plus one
or more of the following variables (if not already included):
CD4+ T-cell count, CD8+ T-cell count, %CD4+ T cells,
%CD8 T cells and CD4+/CD8+ T-cell ratio. In addition, we
executed an LRT comparing the base models against those
ﬁtted with the full set of covariates as previously listed. LRTs
were assessed by considering both the complete MTMR end-
point and the achievement of a CD4+ T-cell count
>500 cells/mm3. As several comparisons were made, we
adjusted the set of p-values obtained with the Bonferroni
correction [24].
All p were two tailed, and values <0.05 were considered
statistically signiﬁcant. The mathematical programming suite
R, with the survival library, was used to perform all statistical
analyses and to generate graphs [25].
Results
Patients’ characteristics
A total of 352 patients, 269 (76.4%) men, met the inclusion
criteria and were followed for a median of 4.1 (IQR 2.1–5.9)
years. Baseline characteristics are shown in Table 1. Among
the 352 patients, only 41 (11.7%) began therapy with CD4+
T-cell counts ‡350 cells/mm3. Each patient had at least one
T-cell marker, among the absolute CD4+ T-cell count,
CD4+ T-cell percentage and CD4+/CD8+ T-cell ratio, lower
than normal at baseline, and 154 (43.7%) had all three of
these markers in the severely low range. A slight majority of
subjects (51.4%) had concordant values of the T-cell markers
in one of the three classes of immune suppression. For
example, among the 41 subjects with baseline CD4+ T-cell
counts >350 cells/mm3, 25 (61%) had %CD4+ T cells £20%
or a CD4+/CD8+ T-cell ratio £0.5.
Recovery of T-cell markers
Among the 352 patients, an absolute CD4+ T-cell count
>500 cells/mm3 was achieved by 270 (76.7%) patients. By
TABLE 1. Patients’ characteristics
Demographics and risk for HIV transmission n (%)
Age (years, mean (IQR)) 39 (34.7–45.7)
Male gender 269 (76.42)
Caucasians 352 (100)
Mode of transmission
Heterosexual 189 (53.7)
MSM 66 (18.7)
Intravenous drug use 74 (21)
Other/unknown 23 (6.5)
Viro-immunological markers and serological status n (%)
HIV RNA (log10 copies/mL, mean (IQR)) 4.87 (4.32–5.28)
CD4+ T-cell count (cells/mm3, mean (IQR)) 190.5 (77–286)
Absolute CD4+ T-cell count
>500/mm3 8 (2.3)
350–500/mm3 33 (9.4)
200–349/mm3 130 (36.9)
<200/mm3 181 (51.4)
CD8+ T-cell count (cells/mm3, mean (IQR)) 841.5 (541.8–1212)
Absolute CD8+ T-cell count
>1200/mm3 91 (25.3)
800–1200/mm3 98 (27.8)
400–799/mm3 116 (32.9)
<400/mm3 47 (13.3)
%CD4+ T-cells 12.8% (6.5–18%)
%CD4+ T-cells
>29% 12 (3.4)
20–29% 51 (14.5)
14–19% 77 (21.9)
<14% 212 (60.2)
CD4+/CD8+ T-cell ratio (mean (IQR)) 0.21 (0.11–0.32)
CD4+/CD8+ T-cell ratio
>1 1 (0.3)
0.5–1 36 (10.2)
0.3–0.49 66 (18.7)
<0.3 249 (70.7)
HBsAb status
Positivity 75 (21.3)
Negativity 157 (44.6)
Unknown 120 (34.9)
HBsAg
Positivity 23 (6.5)
Negativity 252 (71.6)
Unknown 77 (21.8)
HCV-Ab
Positivity 80 (22.7)
Negativity 205 (58.2)
Unknown 67 (19.0)
Antiretroviral therapy n (%)
Antiretroviral regimens
NRTI plus NNRTI 249 (70.7)
NRTI plus PI 22 (6.5)
NRTI plus PI/r 59 (16.8)
Abacavir 22 (6.5)
Clinical events n (%)
Clinical events occurring before baseline
AIDS events 36 (10.2)
Non-AIDS illnesses 82 (23.3)
Non-AIDS neoplasias 3 (0.8)
Clinical events occurring during follow-up
AIDS events 18 (5.1)
Non-AIDS illnesses 54 (15.3)
Non-AIDS neoplasias 5 (1.4)
N, number; IQR, interquartile range; NRTI, nucleos(t)ide reverse transcriptase
inhibitor; NNRTI, non-nucleotide reverse transcriptase inhibitor; PI, protease
inhibitor; PI/r, protease inhibitor boosted with ritonavir.
Among the non-AIDS-related illnesses before HAART initiation cardiovascular
events were found in 10/352 patients, liver diseases in 32/352 patients, meta-
bolic diseases in 38/352 patients and kidney diseases in one patient.
During follow-up, cardiovascular events were found in 4/352 patients, liver dis-
eases in 26/352 patients, metabolic diseases in 9/352 patients. No patients expe-
rienced kidney diseases.
Three neoplasias were found at baseline (one cervical, one kidney and one skin
neoplasia) and ﬁve during the follow-up (three skin, one non-Hodgkin lymphoma
and one connective tissue neoplasia).
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contrast, only 197 (56%) achieved MTMR. By 2 years, the
estimated proportion of patients not reaching an absolute
CD4+ T-cell count >500 cells/mm3 was 0.565 (0.5157–
0.619), whilst that of patients not reaching MTMR was 0.759
(0.715–0.805). By 5 years, estimated proportions were 0.282
(0.2368–0.335) and 0.526 (0.475–0.582), respectively.
Predictors of immune recovery
Predictors of CD4+ T-cell counts to >500 cells/mm3. Table 2
shows univariate and multivariable results for the main mod-
els. The univariate analysis demonstrated a signiﬁcant
increased probability of achieving a CD4+ T-cell count
>500 cells/mm3 for higher baseline absolute CD4+ T-cell
counts, %CD4+ T cells and CD4+/CD8+ T-cell ratio. In con-
trast, increasing age, male gender, non-AIDS-deﬁning cancers
and higher %CD8+ T cells were associated with a signiﬁ-
cantly reduced probability of increasing one’s CD4+ T-cell
count to >500 cells/mm3. In the multivariable analyses, both
higher baseline CD4+ T-cell counts and lower CD8+ T-cell
counts (model 1), higher baseline %CD4+ T cells (model 2),
and higher baseline CD4+/CD8+ T-cell ratio (model 3) were
signiﬁcantly associated with an increased probability of
achieving CD4+ T-cell count to >500 cells/mm3. Additional
variables associated with this outcome were higher pretreat-
ment HIV-1 RNA levels and younger age. In contrast, a diag-
nosis of a non-AIDS-deﬁning cancer was signiﬁcantly
associated with a lower probability of achieving a CD4+
T-cell count to >500/mm3.
As demonstrated in Fig. 1(a), having both a baseline CD4+
T-cell count £350 cells/mm3 and a CD4+/CD8+ T-cell ratio
£0.5 was associated with the lowest probability of reaching
CD4+ T-cell count >500 cells/mm3 by Kaplan–Meier survival
analysis (log-rank p <0.001). If treatment was delayed until
the patient’s CD4+ count was £350 cells/mm3 but the
CD4+/CD8+ T-cell ratio was >0.5 there was a similar rate
of CD4+ T-cell recovery compared with patients whose
baseline CD4+ count was >350 cells/mm3 but had a CD4+/
CD8+ T-cell ratio £0.5.
Predictors of MTMR. Table 3 shows univariate and multivari-
able results for the main models. By multivariable analyses,
both higher CD4+ T-cell count and lower CD8+ T-cell
count at baseline (model 1), both higher %CD4+ T cells and
lower %CD8+ T cells at baseline (model 2), or higher
CD4+/CD8+ T-cell ratio at baseline (model 3) were signiﬁ-
cantly associated with increased probability of MTMR. Other
variables signiﬁcantly associated with this outcome were:
HAART initiation in more recent calendar years (models 1
and 3) and higher HIV-1 RNA level at baseline (models 1
and 2). In contrast, variables signiﬁcantly associated with a
decreased probability of MTMR were: older age (models 1–
3) and a diagnosis of non-AIDS-deﬁning cancers (model 1).
As was the case for achieving a CD4+ T-cell count
>500 cells/mm3, the baseline CD4+ T-cell count and baseline
CD4+/CD8+ T-cell ratio each contributed to the rate at
which patients achieved MTMR (Fig. 1b). The group with a
baseline CD4+ T-cell count £350 cells/mm3 plus a CD4+/
CD8+ T-cell ratio £0.5 had the lowest probability of reach-
ing MTMR by Kaplan–Meier survival analysis (log-rank
p <0.001). Although the hazard ratio (HR) for achieving an
MTMR was not statistically signiﬁcantly in favour of patients
with baseline CD4+ T-cell count £350 cells/mm3 plus a
FIG. 1. Kaplan–Meier survival curve showing the proportion of patients over time not reaching a CD4+ T-cell count >500 cells/mm3 (left panel)
or achieving multiparametric T-cell marker recovery (right panel). Patients are stratiﬁed by CD4+ T-cell counts £ or >350 cells/mm3 and CD4+/
CD8+ T-cell ratios £ or >0.5 at baseline.
CMI Torti et al. Long-term CD4+ and CD8+ reconstitution after ARV 453
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 449–458
T
A
B
L
E
3
.
P
re
d
ic
to
rs
o
f
a
c
h
ie
v
in
g
m
u
lt
ip
le
T
-c
e
ll
m
a
rk
e
r
re
c
o
v
e
ry
T
im
e
-ﬁ
x
e
d
v
a
ri
a
b
le
s
U
n
iv
a
ri
a
te
M
u
lt
iv
a
ri
a
b
le
1
M
u
lt
iv
a
ri
a
b
le
2
M
u
lt
iv
a
ri
a
b
le
3
H
R
(9
5
%
C
I)
p
H
R
(9
5
%
C
I)
p
H
R
(9
5
%
C
I)
p
H
R
(9
5
%
C
I)
p
A
ge
(p
e
r
1
0
ye
ar
s
o
ld
e
r)
0
.6
9
(0
.5
8
–
0
.8
3
)
<
0
.0
0
1
0
.7
7
(0
.6
5
–
0
.9
2
)
0
.0
0
4
0
.7
0
(0
.5
8
–
0
.8
5
)
<
0
.0
0
1
0
.7
3
(0
.6
1
–
0
.8
8
)
0
.0
0
1
M
al
e
s
(v
s.
Fe
m
al
e
)
0
.6
0
(0
.4
5
–
0
.8
1
)
<
0
.0
0
1
0
.9
2
(0
.6
3
–
1
.3
5
)
0
.6
9
4
1
.0
2
(0
.6
9
–
1
.5
4
)
0
.8
9
0
0
.9
9
(0
.6
7
–
0
.8
8
)
0
.9
8
0
B
as
e
lin
e
ye
ar
(p
e
r
1
ye
ar
m
o
re
re
ce
n
t)
1
.0
5
(0
.9
6
–
1
.1
6
)
0
.2
3
8
1
.1
2
(1
.0
1
–
1
.2
4
)
0
.0
2
6
1
.0
7
(0
.9
7
–
1
.1
8
)
0
.1
9
4
1
.1
1
(1
.0
1
–
1
.2
3
)
0
.0
3
9
M
o
d
e
o
f
tr
an
sm
is
si
o
n
H
et
e
ro
se
x
u
al
(r
e
f.)
–
(r
e
f.)
–
(r
e
f.)
–
(r
e
f.)
–
H
o
m
o
/b
is
e
x
u
al
1
.0
0
(0
.7
0
–
1
.4
5
)
0
.9
6
9
0
.9
3
(0
.6
1
–
1
.4
2
)
0
.7
4
5
0
.9
8
(0
.6
2
–
1
.5
2
)
0
.9
1
6
1
.1
2
(0
.7
5
–
1
.6
7
)
0
.5
7
8
In
tr
av
en
o
u
s
d
ru
g
u
se
0
.8
0
(0
.5
6
–
1
.1
5
)
0
.2
3
5
1
.0
6
(0
.6
8
–
1
.6
5
)
0
.7
9
6
0
.9
9
(0
.6
3
–
1
.5
4
)
0
.9
5
3
1
.0
2
(0
.6
7
–
1
.5
8
)
0
.8
9
8
O
th
e
r/
u
n
k
n
o
w
n
0
.5
8
(0
.3
1
–
1
.0
9
)
0
.0
9
8
0
.9
5
(0
.5
–
1
.8
)
0
.8
7
6
0
.8
3
(0
.4
1
–
1
.7
0
)
0
.6
1
8
0
.7
5
(0
.3
7
–
1
.5
0
)
0
.4
1
2
H
B
V
st
at
u
s
H
B
sA
b
p
o
si
ti
vi
ty
(v
s.
n
e
ga
ti
ve
/u
n
k
n
o
w
n
)
0
.9
8
(0
.6
9
–
1
.4
0
)
0
.9
2
4
0
.8
6
(0
.5
7
–
1
.3
1
)
0
.4
8
5
1
.0
3
(0
.6
9
–
1
.5
7
)
0
.8
6
5
0
.9
6
(0
.6
4
–
1
.4
4
)
0
.8
4
0
H
B
sA
g
p
o
si
ti
vi
ty
(v
s.
n
e
ga
ti
ve
/u
n
k
n
o
w
n
)
0
.9
9
(0
.5
5
–
1
.8
1
)
0
.9
8
6
0
.8
5
(0
.4
7
–
1
.5
6
)
0
.6
1
2
0
.9
5
(0
.5
3
–
1
.7
1
)
0
.8
7
7
1
.0
3
(0
5
8
–
1
.8
4
)
0
.9
1
2
H
C
V
A
b
p
o
si
ti
vi
ty
(v
s.
n
e
ga
ti
vi
ty
/u
n
k
n
o
w
n
)
0
.7
9
(0
.5
6
–
1
.1
1
)
0
.1
8
2
0
.7
3
(0
.4
8
–
1
.1
1
)
0
.1
4
9
0
.8
6
(0
.5
5
–
1
.3
5
)
0
.5
2
6
0
.8
9
(0
.5
8
–
1
.3
5
)
0
.5
7
6
C
D
4
+
co
u
n
t
(p
e
r
5
0
ce
lls
/m
m
3
h
ig
h
e
r)
1
.1
4
(1
.0
6
–
1
.2
2
)
<
0
.0
0
1
1
.3
5
(1
.2
6
–
1
.4
6
)
<
0
.0
0
1
N
o
t
e
n
te
re
d
N
o
t
e
n
te
re
d
C
D
8
+
co
u
n
t
(p
e
r
2
0
0
ce
lls
/m
m
3
h
ig
h
e
r)
0
.9
7
(0
.9
2
–
1
.0
2
)
0
.2
1
8
0
.8
5
(0
.7
9
–
0
.9
1
)
<
0
.0
0
1
%
C
D
4
(p
e
r
1
0
%
h
ig
h
e
r)
3
.2
9
(2
.8
0
–
3
.8
6
)
<
0
.0
0
1
N
o
t
e
n
te
re
d
2
.3
0
(1
.8
5
–
2
.8
6
)
<
0
.0
0
1
N
o
t
e
n
te
re
d
%
C
D
8
(p
e
r
1
0
%
h
ig
h
e
r)
0
.7
9
(0
.7
1
–
0
.8
7
)
<
0
.0
0
1
0
.8
6
(0
.7
6
–
0
.9
8
)
0
.0
2
6
C
D
4
+
/C
D
8
+
T
-c
e
ll
ra
ti
o
(p
e
r
0
.3
h
ig
h
e
r)
3
.2
5
(2
.6
5
–
3
.9
9
)
<
0
.0
0
1
N
o
t
e
n
te
re
d
N
o
t
e
n
te
re
d
2
.4
2
(1
.9
9
–
2
.9
5
)
<
0
.0
0
1
H
IV
R
N
A
(p
e
r
lo
g 1
0
h
ig
h
e
r)
1
.1
2
(0
.7
6
–
1
.0
5
)
0
.1
8
7
1
.2
9
(1
.0
8
–
1
.5
5
)
0
.0
0
6
1
.2
1
(1
.0
4
–
1
.4
2
)
0
.0
1
6
1
.1
6
(0
.9
3
–
1
.4
4
)
0
.0
8
5
T
im
e-
va
ry
in
g
va
ri
ab
le
s
A
n
ti
re
tr
o
vi
ra
l
th
e
ra
p
y
N
R
T
I
p
lu
s
N
N
R
T
I
(r
e
f.)
–
(r
e
f.)
–
(r
e
f.)
–
(r
e
f.)
–
N
R
T
I
p
lu
s
P
I
0
.5
8
(0
.2
8
–
1
.2
0
)
0
.1
3
9
0
.6
5
(0
.2
8
–
1
.5
1
)
0
.3
2
1
0
.5
7
(0
.2
6
–
1
.2
3
)
0
.1
5
3
0
.6
(0
.2
7
–
1
.3
3
)
0
.2
0
8
N
R
T
I
p
lu
s
P
I/
r
0
.8
4
(0
.5
6
–
1
.2
5
)
0
.3
8
9
0
.8
2
(0
.5
4
–
1
.2
5
)
0
.3
6
2
1
.0
1
(0
.6
5
–
1
.5
5
)
0
.9
8
3
0
.8
9
(0
.5
8
–
1
.3
7
)
0
.6
1
3
O
th
e
r
1
.4
5
(0
.9
3
–
2
.2
7
)
0
.1
0
0
1
.3
0
(0
.8
4
–
1
.9
9
)
0
.2
3
5
1
.3
2
(0
.8
4
–
2
.0
8
)
0
.2
2
5
1
.2
6
(0
.8
1
–
1
.9
6
)
0
.3
0
5
T
h
e
ra
p
y
lin
e
1
.0
8
(0
.8
2
–
1
.4
2
)
0
.5
6
7
1
.1
3
(0
.8
4
–
1
.5
1
)
0
.4
2
2
1
.1
4
(0
.8
5
–
1
.5
3
)
0
.3
7
0
1
.1
5
(0
.8
6
–
1
.5
3
)
0
.3
4
0
A
ID
S
e
ve
n
ts
0
.6
9
(0
.4
5
–
1
.0
4
)
0
.0
7
5
0
.8
3
4
(0
.4
8
–
1
.4
4
)
0
.5
1
7
0
.8
5
(0
.5
6
–
1
.3
0
)
0
.4
6
3
0
.8
1
(0
.5
2
–
1
.2
7
)
0
.3
5
8
N
o
n
-A
ID
S
e
ve
n
ts
0
.9
6
(0
.7
7
–
1
.1
9
)
0
.7
1
5
1
.0
7
(0
.8
2
–
1
.3
9
)
0
.6
1
1
1
.1
8
(0
.9
3
–
1
.5
0
)
0
.1
6
1
1
.1
6
(0
.9
3
–
1
.4
4
)
0
.1
7
6
N
o
n
A
ID
S-
d
eﬁ
n
in
g
n
e
o
p
la
si
as
0
.6
0
(0
.2
2
–
1
.6
1
)
0
.3
1
3
0
.0
2
(0
.0
0
–
0
.4
1
)
0
.0
1
2
0
.9
2
(0
.4
3
–
1
.9
9
)
0
.8
4
7
0
.5
8
(0
.2
4
–
1
.4
2
)
0
.2
3
5
H
R
,
h
az
ar
d
ra
ti
o
;
9
5
%
C
I,
9
5
%
co
n
ﬁ
d
en
ce
in
te
rv
al
;
p
,
p
ro
b
ab
ili
ty
;
N
R
T
I,
n
u
cl
e
o
s(
t)
id
e
re
ve
rs
e
tr
an
sc
ri
p
ta
se
in
h
ib
it
o
r;
N
N
R
T
I,
n
o
n
-n
u
cl
eo
ti
d
e
re
ve
rs
e
tr
an
sc
ri
p
ta
se
in
h
ib
it
o
r;
P
I,
p
ro
te
as
e
in
h
ib
it
o
r;
P
I/
r,
p
ro
te
as
e
in
h
ib
it
o
r
b
o
o
st
e
d
w
it
h
ri
-
to
n
av
ir
.
M
u
lt
iv
ar
ia
b
le
m
o
d
e
l
1
co
n
si
d
e
re
d
ab
so
lu
te
C
D
4
+
an
d
C
D
8
+
T
-c
e
ll
co
u
n
ts
,
m
u
lt
iv
ar
ia
b
le
2
co
n
si
d
e
re
d
%
C
D
4
+
an
d
%
C
D
8
+
T
ce
lls
an
d
m
u
lt
iv
ar
ia
b
le
3
co
n
si
d
e
re
d
C
D
4
+
/C
D
8
+
T
-c
e
ll
ra
ti
o
as
in
d
e
p
e
n
d
e
n
t
co
va
ri
at
e
.
T
h
e
ra
p
y
lin
e
w
as
d
eﬁ
n
e
d
as
th
e
n
u
m
b
er
o
f
co
m
b
in
at
io
n
s
o
f
an
ti
re
tr
o
vi
ra
l
d
ru
gs
.
E
ve
ry
ch
an
ge
o
f
d
ru
gs
p
ro
d
u
ce
d
a
n
e
w
th
e
ra
p
y
lin
e
.
454 Clinical Microbiology and Infection, Volume 18 Number 5, May 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 449–458
CD4+/CD8+ T-cell ratio >0.5 versus CD4+ T-cell count
>350 cells/mm3 plus a CD4+/CD8+ T-cell ratio £0.5, by ﬁt-
ting a multivariable Cox regression model, with the group
with a CD4+ T-cell count £350 cells/mm3 plus a CD4+/
CD8+ T-cell ratio £0.5 as the reference condition, we found
increasing HR (95% conﬁdence interval, CI) as follows: 3.67
(2.19–6.16, p <0.001) for CD4+ T-cell count >350 cells/mm3
plus a CD4+/CD8+ T-cell ratio £0.5; 4.5 (2.83–7.16,
p <0.001) for CD4+ T-cell count £350 cells/mm3 plus a
CD4+/CD8+ T-cell ratio >0.5; and 8.22 (5.19–13.04,
p <0.001) for CD4+ T-cell count >350/mm3 plus a CD4+/
CD8+ T-cell ratio >0.5.
According to the sensitivity analysis, even in severely
immunologically impaired patients a greater absolute CD4+
T-cell count (HR, 1.07; 95% CI, 1-1.16, p 0.048 per 10
CD4+/mm3 higher) was an independent predictor of MTMR.
By the same model, absolute CD8+ T-cell count was not sig-
niﬁcantly associated with MTMR when ﬁtted numerically.
However, using a stratiﬁcation of CD8+ T-cell counts <400
versus >1100 cells/mm3, a trend towards an increased hazard
of MTMR was observed (HR, 3.60; 95% CI, 0.93–13.94;
p 0.060). Moreover, in separate models, either %CD4+ T
cells (HR, 1.12; 95% CI, 1.02–1.22; p 0.012 per 1% higher) or
CD4+/CD8+ T-cell ratio (HR, 1.25; 95% CI 1.06–1.48;
p 0.007 per 0.04 higher) were independent predictors of
MTMR.
Comparison between absolute CD4+ T-cell count and composite
measures of immune status at baseline for predictions of immune
recovery. When executing LRTs considering different nested
models (Table 4), we found in general that the addition of
other laboratory markers besides the CD4+ T-cell count
alone increased the model ﬁt signiﬁcantly, even after correc-
tion of the p-values with the Bonferroni procedure. With
regard to the endpoint of achieving a CD4+ T-cell count
>500 cells/mm3, starting from the base model with only the
baseline CD4+ T-cell count variable, the addition of the
baseline CD8+ T-cell count covariate did not lead to a signif-
icantly better ﬁt, while the addition of the baseline CD4+/
CD8+ T-cell ratio, or the addition of both baseline %CD4 T
cells and baseline %CD8 T cells, led to a signiﬁcant improve-
ment of the model ﬁt. Conversely, the addition of baseline
CD4+ T-cell count, or baseline CD8+ T-cell count or base-
line %CD4% and %CD8 T cells to the base model made by
the baseline CD4+/CD8+ T-cell ratio alone always led to a
signiﬁcant improvement of the model ﬁt. With respect to
the MTMR endpoint, when starting with the base model
made by the baseline CD4+ T-cell count alone and adding
any of the other above-mentioned covariates, signiﬁcant
improvements in the likelihood were produced. When start-
ing with the base model made by the baseline CD4+/CD8+
T-cell ratio alone, appreciable improvements in the model ﬁt
were found only when adding the baseline %CD4+ and
%CD8+ T cells together.
Notably, the multivariable model made from the full set of
covariates (including all other clinical/demographic variables
besides the immunological markers) always produced a signif-
icantly better ﬁt than any base models for both endpoints.
Discussion
To our knowledge, this is the largest analysis of immune
reconstitution of multiple T-cell markers in patients on pro-
longed suppression of virus replication to levels <50 copies/
mL. We deﬁned an MTMR immunological endpoint that
includes changes in absolute CD4+ T-cell counts, CD4+
T-cell percentage and the CD4+/CD8+ T-cell ratio. Absolute
TABLE 4. Comparison between absolute CD4+ T-cell count and composite measures of immune status at baseline for predic-
tions of immune recovery (likelihood ratio tests).
Endpoint Null (N) Alternative (A) LN LA dfN dfA p-value pB R
2
N R
2
A
CD4+ T-cell
count >500 cells/mm3
CD4+ CD4+ and CD8+ )1364 )1363 1 2 0.1060 1.0000 0.20 0.21
CD4+ and CD4+/CD8+ )1364 )1354 1 2 <0.0001 0.0001 0.20 0.25
CD4+ and CD4% and CD8% )1364 )1347 1 3 <0.0001 <0.0001 0.20 0.28
CD4+/CD8+ CD4+/CD8+ and CD4+ )1366 )1354 1 2 <0.0001 <0.0001 0.20 0.25
CD4+/CD8+ and CD8+ )1366 )1358 1 2 0.0001 0.0008 0.20 0.23
CD4+/CD8+ and CD4% and CD8% )1366 )1360 1 3 0.0013 0.0180 0.20 0.23
CD4+ Full set of covariates )1364 )1323 1 19 <0.0001 <0.0001 0.20 0.42
MTMR CD4+ CD4+ and CD8+ )1020 )1011 1 2 <0.0001 0.0004 0.12 0.15
CD4+ and CD4+/CD8+ )1020 )987 1 2 <0.0001 <0.0001 0.12 0.23
CD4+ and CD4% and CD8% )1020 )971 1 3 <0.0001 <0.0001 0.12 0.27
CD4+/CD8+ CD4+/CD8+ and CD4+ )988 )987 1 2 0.1210 1.0000 0.22 0.23
CD4+/CD8+ and CD8+ )988 )987 1 2 0.1050 1.0000 0.22 0.23
CD4+/CD8+ and CD4% and CD8% )988 )977 1 3 <0.0001 0.0002 0.22 0.26
CD4+ Full set of covariates )1020 )966 1 19 <0.0001 <0.0001 0.12 0.31
MTMR, multiple T-cell marker recovery; L, log-likelihood; d.f., degrees of freedom; pB, Bonferroni’s adjusted p-value; R2, R-squared.
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CD8+ T-cell counts and the CD4+/CD8+ T-cell ratio inde-
pendently predicted immune restoration deﬁned as a CD4+
T-cell count >500 cells/mm3, irrespective of absolute CD4+
T-cell count at baseline. This result is consistent with the
ﬁndings of Castagna et al.[15] after 6 months of effective
therapy. Each of the T-cell markers contributed indepen-
dently to the composite marker. Therefore, MTMR may be a
better predictor of when to initiate antiretroviral therapy,
assuming one therapeutic goal is the most complete level of
immune reconstitution that can be achieved.
This is one of few studies that examine changes in T-cell
markers over a long period of virological suppression;
patients were followed for a median of 4 years and 25% for
6 or more years on effective therapy. As has been previously
reported, the majority (77%) of patients reached CD4+ T-
cell count >500/mm3 [5,6]. However, MTMR was obtained in
only a fraction (56% overall), indicating that reconstitution of
absolute CD4+ T-cell counts does not always reﬂect normal-
ization of T-cell homeostasis. Our data suggest that normali-
zation of T-cell markers continues throughout the period of
continued antiretroviral therapy, in contrast to the plateau
effect described in some studies [6,26,27], but not in others
[5,7]. Interestingly, in the studies (including this report) with
longer follow-up that used a more sensitive level of HIV-1
RNA for inclusion [5,7], the plateau effect was not observed.
This reinforces the importance of maintaining HIV-1 RNA
levels <50 copies/mL to achieve as complete an immunologi-
cal reconstitution as can be achieved.
We are aware of only one other study that evaluated
changes in absolute CD4+ and CD8+ T-cell counts, CD4+
T-cell percentage and the CD4+/CD8+ T-cell ratio during a
similar period of follow-up to that in our study [7]. How-
ever, this report is based on only 49 patients, and a viral
load of <400 HIV-1 RNA copies/mL was used to deﬁne
effective therapy, a cut-off that does not exclude periods of
incomplete viral suppression.
A decline in CD8+ T-cell counts is likely to be a hallmark
of the most profound period of immune suppression in the
life of someone with HIV [1]. The combination of a low
CD4+ and CD8+ T-cell count may represent a state of
immune deﬁciency that is difﬁcult to reverse. This may
explain why absolute CD8+ T-cell counts in patients with
CD4+ T < 200 cells/mm3 failed to predict CD4+ T-cell
recovery in our sensitivity analysis.
Our study is too small to infer the clinical relevance of
MTMR in contrast to absolute CD4+ T-cell count recovery
alone. However, per cent CD4+ T cells has been shown to
be an independent predictive factor of AIDS progression
[16], and in other studies the CD4+/CD8+ T-cell ratio was a
predictor of risk for Hodgkin’s lymphoma [17] and myocar-
dial infarction [18,19] independent from other clinical and
immunological factors.
We examined other clinical factors that predicted
increases of CD4+ T-cell counts to >500 cells/mm3 and
MTMR. Younger patients had a better chance of achieving
these outcomes, as has been described [28]. In addition,
patients with higher baseline HIV-1 RNA levels were more
likely to achieve both an increase in CD4+ T-cell count to
>500 cells/mm3 and MTMR, which is similar to ﬁndings in
several studies [3,29–31]. Patients with a diagnosis of non-
AIDS-related malignancies were less likely to achieve these
immunological thresholds, possibly due to damage by chemo-
therapy. Lastly, patients who started treatment in more
recent years had higher probabilities of reaching MTMR.
Our study has several limitations. Because we focused
only on patients with sustained virological suppression we
cannot make any conclusion about the effects of intermittent
increases in virus replication to measureable levels, and
therefore, these data are not representative of the immuno-
logical changes in many patients cared for in clinical practice.
Because of the sample size we were not able to make any
observations on the impact of speciﬁc classes of antiretrovi-
ral therapy on immunological recovery, which has been
shown to inﬂuence the magnitude of CD4+ T-cell recovery
according to some studies [32,33], but not to others
[34–36]. Moreover, other possible factors such as viral
phenotype (CCR5-tropic versus CXCR4-tropic strains) or
drug-resistance signature mutations at entry were not
considered in this study.
In addition, we used single measurements of baseline and
endpoint CD4+ T-cell counts. One might argue that a single
CD4+ T-cell count measurement could be imprecise, and
the usage of a linear mixed model approach might be more
appropriate [37], because it has the added advantage of esti-
mating mean and subject-speciﬁc slope estimates. However,
the MTMR endpoint was a combined indicator and should be
more robust as compared with a putative transient achieve-
ment of just one indicator over a certain threshold (for
instance a CD4+ T-cell count >500 cells/mm3). In addition,
the usage of single baseline measurements keeps the model
simpler and applicable in clinical practice. Further directions
could include the comparison of our simple approach with
another model based on slope estimation to evaluate
whether a more complex model improves predictive power
and clinical utility.
In conclusion, our results suggest for the ﬁrst time that
allowing any of the commonly monitored T-cell parameters,
absolute CD4+ T-cell counts, CD4+ T-cell percentage and
CD4+/CD8+ T-cell ratio, to fall below certain thresholds will
compromise a patient’s ability to achieve an absolute CD4+
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T-cell count >500 cells/mm3. Therefore, larger studies are
needed to evaluate if each of these markers should be con-
sidered in deciding when to initiate antiretroviral therapy. It
is important to note that to include these markers in clinical
practice, the results of more studies (ideally randomized clin-
ical trials) are mandatory. Moreover, if our results are con-
ﬁrmed and clinically validated, discussions of immune
reconstitution in HIV patients should include normalization
of these parameters as well as absolute CD4+ T-cell counts.
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